Avanafil

Active ingredient description

Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
G04BE10
Avanafil
G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction
Discover more medicines within G04BE10

Medicines

Avanafil is the active ingredient of these drugs:

Drug
Countries
SPEDRA

Australia Austria Cyprus Finland France

STENDRA

United States

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
SPEDRA Tablet
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

DR5S136IVO - AVANAFIL

CAS registry number

330784-47-9 - avanafil

SNOMED-CT

703956007 - Avanafil (substance)

Next: Usage